(FM) Inmunología
Departamento académico
The Bristol-Myers Squibb Children's Hospital
Nuevo Brunswick, Estados UnidosPublicaciones en colaboración con investigadores/as de The Bristol-Myers Squibb Children's Hospital (14)
2024
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
2022
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
2021
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
2020
-
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Immunity, Vol. 52, Núm. 5, pp. 856-871.e8
2019
-
An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors
Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6709-6720
2018
-
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes
Cancer Immunology Research, Vol. 6, Núm. 1, pp. 69-78
-
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)
OncoImmunology, Vol. 7, Núm. 1
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
-
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936
2016
-
Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming
Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005
-
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Drugs, Vol. 76, Núm. 9, pp. 925-945
2015
-
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Nature Reviews Cancer, Vol. 15, Núm. 8, pp. 457-472
2013
-
T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes
Journal of Immunology, Vol. 190, Núm. 12, pp. 6694-6706